| HAIFA, Israel--(BUSINESS WIRE)--Sept. 12, 2006--Pluristem Life
Systems, Inc. (OTCBB:
PLRS - News)
announces they have been chosen to present at the 35th Annual Scientific
Meeting of the International Society for Experimental Hematology in
Minneapolis, Minnesota September 27- 30, 2006. The meeting will
highlight the important role and personal impact the Society has made in
the field of experimental hematology. Speakers from around the world
will gather with Ora Burger, VP R&D of Pluristem Life Systems, chosen to
discuss the stem cell product PLX-BMT, Pluristem's potential breakthrough
solution that could be used to replace the traditional bone marrow
transplant search and match process. Zami Aberman, Pluristem CEO,
states, "Pluristem has been chosen from many other stem cell companies
because of the true breakthrough we believe we have achieved regarding
bone marrow transplants. We will take the opportunity to address our
colleagues in the scientific community that sufficient engraftment is
definitely possible with a limited number of hematopoietic stem cells
available in a single portion of umbilical cord blood. Our PLX-BMT product
paves the way towards using umbilical cord blood instead of bone marrow
transplants for adult patients. It improves the effectiveness of
engraftments and shortens recovery times. If additional animal studies
and human clinical trials prove equally successful, our PLX-BMT product
could lead to wider use in bone marrow transplants and various types of
blood cancer. Nearly 100,000 people could benefit from this treatment
annually."
About Pluristem
Pluristem Life Systems, Inc. is a life sciences driven company that is
developing and commercializing stem cell expansion technology products
for the treatment of severe blood disorders. The Company is discovering
and developing cell-based therapeutics that utilizes adult stem cells
expanded in a proprietary bioreactor mimicking different naturally
occurring physiological environments. Pluristem expects its first
products to be cell grafts that will provide an efficient and superior
alternative to the standard procedure of bone marrow transplantation.
Its first adult stem cell product targets a critical global shortfall of
matched tissue for bone marrow transplantation since bone marrow
transplantation is often the only cure for patients suffering from
leukemia, lymphoma, myeloma and many other hematological diseases. The
Company has made a strategic decision to work only with adult stem cells
since the practical use of embryonic stem cells is severely restricted
by various religious, ethical and legal considerations.
www.pluristem.com/default.asp
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include
statements: that our company will discuss the stem cell product PLX-BMT at
the Hematology conference, that Pluristem has achieved a breakthrough
solution that could be used to replace the traditional bone marrow
transplant search and match process; that sufficient engraftment is
definitely possible with a limited number of hematopoietic stem cells
available in a single portion of umbilical cord blood;that our PLX-1
product paves the way towards using umbilical cord blood instead of bone
marrow transplants for adult patients improving the effectiveness of
engraftments and shortening recovery times;that if additional animal
studies and human clinical trials prove equally successful, our PLX-BMT
product could lead to wider use in bone marrow transplants and various
types of blood cancer; that we expect our first products to be cell
grafts that will provide an efficient and superior alternative to the
standard procedure of bone marrow transplantation; and our first adult
stem cell product targets a critical global shortfall of matched tissue
for bone marrow transplantation. Factors which may significantly change
or prevent our forward looking statements from fruition include that the
Congress may not proceed; that our VP Ora Burger may not be able to
appear and speak for some reason; that we may be unsuccessful in
developing any products; that our technology may not be validated as we
progress further and our methods may not be accepted by the scientific
community; that we are unable to retain or attract key employees whose
knowledge is essential to the development of our products; that
unforeseen scientific difficulties develop with our process; that
results in the laboratory do not translate to equally good results in
real surgical settings; that our patents are not sufficient to protect
essential aspects of our technology; that competitors may invent better
technology; that our products may not work as well as hoped or worse,
that our products may harm recipients; and that we may not be able raise
funds for development or working capital when we require it. As well,
our products may never develop into useful products and even if they do,
they may not be approved for sale to the public. For further risk
factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
